The molecular mechanisms of congenital hypofibrinogenaemia
- 1 June 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cellular and Molecular Life Sciences
- Vol. 61 (12)
- https://doi.org/10.1007/s00018-004-3458-8
Abstract
Congenital hypofibrinogenaemia is characterized by abnormally low levels of fibrinogen and is usually caused by heterozygous mutations in the fibrinogen chain genes (α, β and γ). However, it does not usually result in a clinically significant condition unless inherited in a homozygous or compound heterozygous state, where it results in a severe bleeding disorder, afibrinogenaemia. Various protein and expression studies have improved our understanding of how mutations causing hypo- and afibrinogenaemia affect secretion of the mature fibrinogen molecule from the hepatocyte. Some mutations can perturb chain assembly as in the γ153 Cys → Arg case, while others such as the Bβ Leu → Arg and the Bβ414 Gly → Ser mutations allow intracellular hexamer assembly but inhibit protein secretion. An interesting group of mutations, such as γ284 Gly → Arg and γ375 Arg → Trp, not only cause hypofibrinogenaemia but are also associated with liver disease. The nonexpression of these variant chains in plasma fibrinogen is due to retention in the endoplasmic reticulum, which in turn leads to hypofibrinogenaemia.Keywords
This publication has 45 references indexed in Scilit:
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsThe New England Journal of Medicine, 2010
- Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery DiseaseThe New England Journal of Medicine, 2010
- Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantationAmerican Heart Journal, 2009
- 3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions: The SPIRIT II Trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions)JACC: Cardiovascular Interventions, 2009
- Safety and Efficacy of Drug-Eluting and Bare Metal StentsCirculation, 2009
- Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort StudyJournal of the American College of Cardiology, 2008
- Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic ModelJournal of the American College of Cardiology, 2008
- Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in SwedenThe New England Journal of Medicine, 2007
- First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial.2005
- Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in HumansCirculation, 2002